TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether TD-1792 is safe and effective when used to
treat complicated skin and skin structure infections caused by Gram-positive bacteria.
Phase:
Phase 2
Details
Lead Sponsor:
Theravance Biopharma Theravance Biopharma Antibiotics, Inc.